dc.contributor
[Waeschle B] Institute of Pharmaceutical and Medicinal Chemistry, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Merz Therapeutics GmbH, Frankfurt a.M., Germany. [Lee J, Kölsche T, Jansen R] Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. [Banach M] Department of Neurology, Collegium Medicum, Jagiellonian University, Kraków, Poland. [Ochudlo S] Medical Practice Dr. Stanislaw Ochudlo, Katowice, Poland. [Salazar G] Servei de Neurologia, Hospital Universitari de Terrassa (CST), Terrassa, Spain
dc.contributor
Consorci Sanitari de Terrassa
dc.contributor.author
Waeschle, Benjamin
dc.contributor.author
Lee, John-Ih
dc.contributor.author
Kölsche, Tristan
dc.contributor.author
Jansen, Robin
dc.contributor.author
banach, marta
dc.contributor.author
Ochudlo, Stanislaw
dc.contributor.author
Salazar, Gabriel
dc.date.accessioned
2025-10-24T08:28:41Z
dc.date.available
2025-10-24T08:28:41Z
dc.date.issued
2025-09-03T11:27:12Z
dc.date.issued
2025-09-03T11:27:12Z
dc.date.issued
2025-04-05
dc.identifier
Waeschle B, Lee JI, Kölsche T, Jansen R, Banach M, Ochudlo S, et al. Protocol and Demographics of the RELY-CD Study: Assessing Long-Term Clinical Response to Botulinum Neurotoxin in Cervical Dystonia. Toxins (Basel). 2025 Apr 5;17(4):180.
dc.identifier
http://hdl.handle.net/11351/13609
dc.identifier
10.3390/toxins17040180
dc.identifier.uri
https://hdl.handle.net/11351/13609
dc.description.abstract
Cervical dystonia; Botulinum neurotoxin; Long-term response
dc.description.abstract
Distonia cervical; Neurotoxina botulínica; Tractament de llarg termini
dc.description.abstract
Distonía cervical; Neurotoxina botulínica; Tratamiento de largo plazo
dc.description.abstract
The RELY-CD study investigated the long-term clinical response to botulinum neurotoxin type A in cervical dystonia within a multicenter, real-world setting. This retrospective study focused on patients treated with complex-free (incobotulinumtoxinA) and complex-containing (onabotulinumtoxinA and abobotulinumtoxinA) BoNT/A formulations over an up to 10-year period. The novel dose-effect parameter "DEff" was introduced to quantify the relationship between dose adjustments and clinical outcomes, enabling the identification of partial treatment failures. The primary endpoint was a comparison of a clinically meaningful worsening in DEff in treatment year 7 compared to year 2 between complex-free and complex-containing botulinum neurotoxin type A. The RELY-CD study provides unique insights into long-term treatment patterns, clinical resistance phenomena, and the implications of formulation differences on treatment outcomes, addressing a critical gap in the literature on real-world botulinum neurotoxin type A application. The study methodology, including the definition and calculation of the novel DEff, as well as clinical baseline characteristics, are presented.
dc.description.abstract
The study was funded by Merz Therapeutics GmbH (Frankfurt a.M., Germany).
dc.format
application/pdf
dc.relation
https://www.doi.org/10.3390/toxins17040180
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Toxina botulínica - Assaigs clínics
dc.subject
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Metalloendopeptidases::Botulinum Toxins::Botulinum Toxins, Type A
dc.subject
Other subheadings::Other subheadings::Other subheadings::/administration & dosage
dc.subject
DISEASES::Nervous System Diseases::Nervous System Diseases::Neurologic Manifestations::Dyskinesias::Dystonia::Torticollis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::hidrolasas::péptido hidrolasas::endopeptidasas::metaloendopeptidasas::toxinas botulínicas::toxinas botulínicas de tipo A
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso::manifestaciones neurológicas::discinesias::distonía::tortícolis
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.title
Protocol and Demographics of the RELY-CD Study: Assessing Long-Term Clinical Response to Botulinum Neurotoxin in Cervical Dystonia
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
